FDA Identifies Excipients At Risk for Potential Melamine Contamination; Issues Alert That New USP Standards for Heparin Products Will Result in Decreased Potency
This article was originally published in PharmAsia News
Executive Summary
FDA officials have alerted pharmaceutical manufacturers and suppliers of 23 drug excipients that may be at risk for melamine contamination and outlined certain compendial and non-compendial procedures to follow for better detecting its presence